Sunshine Heart Announces First Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Tue May 13, 4:00AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) today announced its financial results and provided a corporate update for the first quarter ended March 31, 2014.
Sunshine Heart to Release First Quarter 2014 Results on May 13, 2014
GlobeNewswire - Tue May 06, 4:30AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its first quarter 2014 results will be released on Tuesday, May 13, 2014, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.
Sunshine Heart names Kimberly Oleson as SVP of Clinical Affairs
M2 - Mon Apr 28, 6:18AM CDT
Medical device company Sunshine Heart (NasdaqCM:SSH) revealed on Monday the addition of Kimberly Oleson as senior vice president of its Clinical Affairs.
Sunshine Heart Appoints Kimberly Oleson as Senior Vice President, Clinical Affairs
GlobeNewswire - Mon Apr 28, 4:30AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Kimberly Oleson to the post of Senior Vice President, Clinical Affairs. In this capacity, Ms. Oleson will manage all aspects of the Company's US pivotal study (COUNTER HF(TM)) and EU post-market study (OPTIONS HF) for its flagship C-Pulse(R) Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure.
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 18, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Sunshine Heart (SSH) Is Plunging Today
at The Street - Tue Mar 11, 1:19PM CDT
Sunshine Heart (SSH) plunges after the company, known for its C-Pulse Heart Assist System to treat moderate to severe heart failure, reported a fourth-quarter loss per share that was wider than analysts' expectations and also provided a discouraging...
Sunshine Heart Announces Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update
GlobeNewswire - Tue Mar 11, 4:15AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) today announced its financial results and provided a corporate update for the fourth quarter and full-year ended December 31, 2013.
Sunshine Heart Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Fri Feb 28, 2:54PM CST
Sunshine Heart, Inc. (Nasdaq:SSH), today announced that on February 27, 2014, the Compensation Committee of its Board of Directors approved eleven equity awards under Sunshine Heart's New-Hire Equity Incentive Plan, as material inducements to eleven individuals' entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
Sunshine Heart to Release Fourth Quarter and Year-End 2013 Results on March 11, 2014
GlobeNewswire - Wed Feb 26, 11:28AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its fourth quarter and year-end 2013 results will be released on Tuesday, March 11, 2014, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.
Sunshine Heart to Attend Upcoming Investor Conferences
GlobeNewswire - Wed Feb 26, 4:15AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that the company is scheduled to present a corporate update at the following upcoming investor conferences in March, 2014:
Sunshine Heart to Appear on Bloomberg Television's Taking Stock
GlobeNewswire - Wed Feb 05, 4:15AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that Chief Executive Officer, Dave Rosa, will be featured on Bloomberg Television's Taking Stock on Wednesday, February 5, 2014 at 5:00 pm EST. Hosted by Bloomberg anchor Pimm Fox, Taking Stock is a daily investment-focused program featuring conversations with leading Wall Street analysts, fund managers and CEOs, offering insight into company news, market and trading strategies across equities, fixed income, commodities, and currencies. Following the segment, a link to a recording of the program will be posted to the investor page of Sunshine Heart's website at: http://ir.sunshineheart.com.
Sunshine Heart Provides Corporate Update
GlobeNewswire - Mon Jan 13, 4:15AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today provided a corporate update in advance of the 2014 J.P. Morgan Healthcare Conference, taking place January 13 through 17 in San Francisco.
New Ideas Offer Hope for Both Heart Failure Patients and Investors
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Dec 16, 1:55PM CST
Steep valuations and uncertainty about adoption have created a lot of volatility in the shares of HeartWare International and Thoratec , the leading developers of ventricular assist devices or VADs that help seriously ill heart failure patients...
Nasdaq stocks posting largest volume increases
AP - Thu Sep 19, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Sunshine Heart prices 3.8M shares at $10.50 each
AP - Thu Sep 19, 3:03PM CDT
EDEN PRAIRIE, Minn. (AP) — Sunshine Heart Inc., which makes medical devices to treat heart failure, said Thursday that it priced its stock offering of 3.8 million shares at $10.50 each. The company expects about $37 million in proceeds after expenses.
Sunshine Heart, Inc. Prices $40.0 Million Public Offering of Common Shares
GlobeNewswire - Thu Sep 19, 8:23AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the pricing of its previously announced offering of 3,810,000 shares of its common stock at a price to the public of $10.50 per share in an underwritten public offering pursuant to its effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint book-running managers and Lazard Capital Markets LLC is acting as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. are acting as co-managers for the offering. In addition, Sunshine Heart has granted the underwriters a 30-day option to purchase up to an additional 571,500 shares solely to cover over-allotments, if any. The offering is expected to close on or about September 24, 2013, subject to customary closing conditions.
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares
GlobeNewswire - Wed Sep 18, 3:01PM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that it has commenced an underwritten public offering of its common stock pursuant to its effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint book-running managers and Lazard Capital Markets LLC is acting as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. are acting as co-managers for the offering. In addition, Sunshine Heart expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The offering is subject to customary conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Sunshine Heart Implants First Patient in C-Pulse(R) COUNTER HF(TM) U.S. Pivotal Trial
GlobeNewswire - Thu Sep 12, 4:15AM CDT
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first patient implant in the Company's U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse's unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.